MilliporeSigma Wins CPhI Pharma Award for Excellence in Innovation

October 15, 2018

The company was awarded for excellence in innovation for Parteck MXP Excipient and modified amino acids.

On Oct. 12, 2018, MilliporeSigma announced that it won two CPhI Pharma Awards for innovative products for the pharmaceutical industry. The awards were announced at CPhI’s award gala in Madrid, Spain.

“At MilliporeSigma, we provide innovations that help our customers advance science and accelerate access to better health for people everywhere,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in a company press release. “We are pleased that CPhI has recognized our commitment to drive the industry forward and empower researchers and scientists with products that improve drug development quality and efficiency.”

The company received the following awards:

  • Parteck MXP Excipient won for “Excellence in Excipients.” The product is a new polyvinyl alcohol excipient for the formulation of stable amorphous solid dispersions by hot melt extrusion. It offers enhanced API solubility and stable, high drug loads. The new excipient is applicable for a variety of final formulations with different release kinetics and offers the formulator flexibility in designing a drug product that fits the respective API and desired therapeutic effect.

  • MilliporeSigma’s modified amino acids won for “Excellence in Bioprocessing and Manufacturing.” The modified amino acids Phospho-Tyrosine disodium salt and Sulfo-Cysteine sodium salt are components for biomanufacturing and mAb processes, designed to simplify fed-batch processes in applying a single-feed strategy.

The CPhI Pharma Awards celebrate thinkers and creators breaking new ground in the industry and advocate companies that are committed to driving the industry forward. CPhI Wordwide was held in Madrid on Oct. 9–11, 2018.

Source: MilliporeSigma